Pharmacological treatment of acute myocardial infarction in public hospitals of Andalucía, Spain;Evaluación del tratamiento farmacológico del infarto de miocardio en los hospitales púlicos de Andalucía

Medicina Clinica

Volumn 111, Issue 9, 1998, Pages 329-335

  Paloma, Francisco Javier Bautista ^a   Muñoz, Nuria Muñoz ^b   Rueda, Enrique Gordillo ^b   Ramos, Bernardo Santos ^b   García, Francisco Javier Cobos ^b   Aznar, M Dolores Guerrero ^b  

^a HOSPITAL DE LA MERCED   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; NITRATE; STREPTOKINASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL PRACTICE; DRUG EFFECT; DRUG UTILIZATION; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PUBLIC HOSPITAL; SPAIN; AGE; COMPARATIVE STUDY; HEART INFARCTION; MIDDLE AGED; PROSPECTIVE STUDY; SEX DIFFERENCE;

AGE FACTORS; AGED; ANTICOAGULANTS; ASPIRIN; DRUG UTILIZATION; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HOSPITALS, PUBLIC; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NITRATES; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; SEX FACTORS; SPAIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0032569363     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Sanz G, Cabadés A, Fernández C, López L, Marin E, Pajarón A et al. Informe sobre «tratamiento trombolítico en cardiologia». Informacion TerapéutSistemaica del Sistema Nacional de Salud 1994; 17: 265-280.
2. Instituto de Estadistica de Andalucia. Estadisticas de Mortalidad de la Junta de Andalucía 1996: INFOIEA, 1997.
3. Cairns JA, Fuster V, Gore J, Ward Kennedy J. Coronary Thrombolysis. Chest 1995; 108 (Supl): 401-423.
4. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402.
5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Larcet 1988; 2: 349-360.
6. Fibrinolytic Therapy Trialist's (FIT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from ali randomised trials of more than 1.000 patients. Lancet 1994; 343: 311-322.
7. Gruppo Italiano per lo Studio della Sopravviverza nell'Infarto Miocardico. GISSI-2 a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12.490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71.
8. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomized comparison of streptokinase vs tissue plasminoger activator vs anistreplase and of aspirin plus heparin vs heparin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-770.
9. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682
10. Simoons ML, Arnold AE. Tailored thrombolytic therapy. A perspective. Circulation 1993; 88: 2.556-2.564.
11. Habib GB. Current status of thrombolysis in acute myocardial infarction. Part II: optimal utilization of thrombolysis in clinical subsets. Chest 1995; 107: 528-534.
12. Pilote L, Califf RM, Sapp S, Miller DP, Mark DB, Weaver WD et al, for the GUSTO Investigators. Regional variation across the United States in the management of acute myocardial infarction. N Engl J Med 1995; 333: 565-572.
13. Van de Werf F, Topol EJ, Lee KL, Woodlief LH, Granger CB, Armstrong PW et al, for the GUSTO Investigators. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. JAMA 1995; 273: 1.586-1.591.
14. López-Sendón J, López de Sá E, Bobadilla JF, Rubio R, Bermejo J, Delcán JL. Efectividad de los diferentes fármacos trombolíticos en el tratamiento del infarto agudo de miocardio. Rev Esp Cardiol 1995; 48: 407-439.
15. LATE Study Group. Late Assessment of Thrombolysis Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993; 342: 759-766.
16. EMERAS (Estudio Multicéntrico Estreptocinasa Repúblicas de América del Sur) Collaborative Group. Randomized trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993; 342: 767-772.
17. Mark D, Hlatky M, Califf R, Naylor CD, Lee KL, Armstrong PW et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1.418-14.24.
18. GAUME. Utilización de fibrinolíticos en los hospitales publicos de Andalucía. ITSNS 1996; 20: 103-110.
19. Ketley D, Woods KL, for the European Secondary Prevention Study Group. Selection factors for the use of thrombolytic treatment in acute myocardial infarction a population based study of current practice in the United Kingdom Br Heart J 1995; 74: 224-228.
20. Becker RC. Coronary thrombolysis in the treatment of women with acute myocardial infarction. Cardiology 1995; 86: 299-303.
21. Romero C, Martínez L. Trombólisis coronaria y edad. Rev Esp Cardiol 1995; 48 (Supl 3): 59-63.
22. Ketley D, Woods KL. Impact of clinical trials on clinical practice example of thrombolysis for acute myocardial infarction. Lancet 1993; 342: 891-894.
23. Venturini F, Romero M, Tognoni G. Acute myocardial infarction treatments in 58 Italian hospitals: a drug utilization survey. Ann Pharmacother 1995; 29: 1.100-1.105.
24. Europen Secondary Prevention Study Group. Traslation of clinical trials into practice: an European population-based study of the use of thrombolysis for acute myocardial infarction. Lancet 1996; 347: 1.203-1.207.
25. Saltissi S, Mushahwar SS. The management of acute myocardial infarction. Postgrad Med J 1995; 71: 534-541.
26. White HD, Barbash GI, Califf RM, Simes RJ, Granger CB, Weaver WD et al. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-1 trial. Circulation 1996; 94: 1.826-1.833.
27. National Heart Attack Alert Program Coordinating Comitee Access to Care Subcommittee. Staffing and equipping Emergency Medical Services System: rapid identification and treatment of acute myocardial infarction. Am J Emerg Med 1995; 13: 58-65.
28. National Heart Attack Alert Program Coordinating Comitee Access to Care Subcommittee. Emergency medical dispatching: rapid identification and treatment of acute myocardial infarction. Am J Emerg Med 1995; 13: 67-72.
29. Grijseels EW, Bouten MJ, Lenderink T, Deckers JW, Hoes AW, Hartman JA et al. Prehospital thrombolytic therapy with either alteplase or streptokinase. Eur Heart J 1995; 16: 1.833-1.838.
30. Habib GB. Current status of thrombolysis in acute myocardial infarction. Part III: optimalization of adjuntive therapy after thrombolytic therapy. Chest 1995; 107: 809-816.
31. First International Study of Infarct Survival Collaborative Group. Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction. ISIS-1. Lancet 1986; 2: 57-66.
32. Bermejo J, Martín JF, Alonso J, Durán JM, Gimeno de Carlos F, Muńoz JC et al. Impacto de las nuevas estrategias de tratamiento del infarto agudo de miocardio sobre la mortalidad hospitalaria de una poblacion con edad superior a 64 anos. Rev Esp Cardiol 1995: 48 (Supl 3): 36-43.
33. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4. A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
34. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1.115-1.122.
35. Rutherford J, Pfeffer M, Moyé L, Davis BR. Falker GC, Kowey PR et al. Effects of captopril on ischemic events after myocardial infarction. Circulation 1994; 90: 1.731-1.738.
36. Julian DG. Should ACE inhibitors be administered to all patients after acute myocardial infarction? A (catious) negative response. Eur Heart J 1995; 16 (Supl E): 44-45.
37. Cleeland JG. ACE inhibitors for myocardial infarction how should they be used? Eur Heart J 1995; 16: 153-159.
38. Prashad R, Lamas GA. Should ACE inhibitors be administered to all patients after acute myocardial infarction? Eur Heart J 1995; 16 (Supl E): 41-43.
39. Kyriakidis M, Antonopoulos A, Georgiou E, Santas P, Bakirtzis C, Toutouzas P. Captopril adjuvant therapy to beta-blockers and nitrates improves post-myocardial infarction left ventricular performance. Eur Heart J 1996; 17: 864-873.
40. Jugdutt BI. Effect of nitrates on myocardial remodeling after acute myocardial infarction. Am J Cardiol 1996; 77: 17-23.
41. Hampton EM, Whang DD, Whang R. Intravenous magnesium therapy in acute myocardial infarction. Ann Pharmacother 1994; 28: 212-219.
42. Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992; 339: 1.553-1.558.
43. Woods XL, Fletcher S. Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction. The second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1994; 343: 816-819.